The development of new therapeutics for Alzheimer's disease (Q37784685)

23 August 2017

The development of new therapeutics for Alzheimer's disease (English)

1 reference

23 August 2017

0 references

M D Carter

1

1 reference

23 August 2017

G A Simms

series ordinal

2

1 reference

23 August 2017

D F Weaver

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Clinical Pharmacology & Therapeutics

23 August 2017

1 reference

23 August 2017

88

1 reference

23 August 2017

4

1 reference

23 August 2017

475-486

1 reference

Alzheimer's disease and Parkinson's disease

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Protein aggregation diseases: pathogenicity and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Alzheimer's disease: strategies for disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Current therapeutic targets for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Tau protein pathology in neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Pathways towards and away from Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Effects of specific protease inhibitors on amyloid beta-protein 42 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Causative and susceptibility genes for Alzheimer's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

A beta oligomers - a decade of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Beta-amyloid monomers are neuroprotective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Intracellular amyloid-beta in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Inhibition of Alzheimer beta-fibrillogenesis by melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Modified-peptide inhibitors of amyloid beta-peptide polymerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Peptide inhibitors of beta amyloid aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Secretase as a target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Inhibition of BACE, a promising approach to Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Cholesterol and the biology of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Therapeutic approaches for prion and Alzheimer's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Therapies for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

inferred from DOI database lookup

7 January 2021

based on heuristic

Proceedings of the SGA Launch Symposium and the 15th Novo Nordisk Symposium on Growth Hormone and Endocrinology. April 1-3, 2004. Malta

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

inferred from DOI database lookup

7 January 2021

based on heuristic

GSK-3 is essential in the pathogenesis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.165

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.165

1 reference

23 August 2017

1 reference